

TECHNICAL DATA SHEET

In Vivo Ready™ Anti-Human CD3 (Hit3a)

Catalog Number: 40-0039

PRODUCT INFORMATION

Contents: In Vivo Ready™ Anti-Human CD3 (Hit3a)

Isotype: Mouse IgG2a, kappa

Concentration: 2 mg/mL

Clone: Hit3a

Reactivity: Human

Formulation: 10 mM NaH₂PO₄, 150 mM NaCl, pH7.2

Endotoxin Level: Less than or equal to 0.01 EU/ug, as determined by the LaL assay

DESCRIPTION

The Hit3a antibody is specific for human CD3e, also known as CD3 epsilon, a 20 kDa subunit of the T cell receptor complex, along with CD3 gamma and CD3 delta. These integral membrane protein chains assemble with additional chains of the T cell receptor (TCR), as well as CD3 zeta chain, to form the T cell receptor – CD3 complex. Together with co-receptors CD4 or CD8, the complex serves to recognize antigens bound to MHC molecules on antigen-presenting cells. These interactions promote T cell receptor signaling (T cell activation), inducing cell proliferation, differentiation, production of cytokines or activation-induced cell death. CD3 is differentially expressed during thymocyte-to-T cell development and on all mature T cells. The Hit3a antibody is a widely used phenotypic marker for human T cells. In addition, binding/cross-linking of Hit3a antibody to CD3e can induce cell activation. The antibody has also been demonstrated to be cross-reactive with Chimpanzee CD3.

PREPARATION & STORAGE

This monoclonal antibody preparation was purified from tissue culture supernatant via affinity chromatography. For In Vivo Ready™ (IVR) products, each preparation is also evaluated for endotoxin levels using the LAL assay. It is recommended to store the product undiluted at 4°C. Do not freeze.

APPLICATION NOTES

This purified format is guaranteed to be >90% pure as determined by SDS-PAGE analysis. Citations are provided as a convenience to you - please consult Materials and Methods sections for additional details about the use of any product in these publications.

REFERENCES

Lesourne R, Zvezdova E, Song K-D, El-Khoury D, Uehara S, Barr VA, Samelson LE and Love PE. 2012. J. Immunol. 189: 1154-1161. (in vitro activation)Knyazhitsky M, Moas E, Shaginov E, Luria A, and Braiman A. 2012. J. Biol. Chem. 287: 19725-19735. (in vitro activation)Ge Shuwang, Hertel B, Emden SH, Beneke J, Menne J, Haller H, and von Vietinghoff S. 2012. Nephrol. Dial. Transplant. 27: 2768-2772. (immunofluorescence microscopy)Soto PC, Stein LL, Hurtado-Ziola N, Hedrick SM, and Varki A. 2010. J. Immunol. 184: 4185-4195. (flow cytometry – Chimpanzee)Westermann J, Bode U, Sahle A, Speck U, Karin N, Bell EB, Kalles K, and Gebert A. 2005. J. Immunol. 174: 2517-2524. (immunohistochemistry – frozen tissue)Mukouyama H, Janzen NK, Hernandez JM, Lam JS, Caliliw R, Wang AY, Figlin RA, Beldegrun AS, and Zeng G. 2004. Clin. Cancer Res. 10: 1421-1429. (in vitro blocking)

NOTE: Please choose the appropriate format for each application. Citations are provided as a convenience to you; please consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.

Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Tonbo Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Tonbo Biosciences, Tonbo Biosciences Logo and all other trademarks are the property of Tonbo Biotechnologies Corporation. © 2013 Tonbo Biosciences.